An analysis of how functional outcomes are measured in patients with soft tissue sarcoma revealed the efficacy of salvage surgery, and a need to improve frequency of FO measurements.
Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Investigators from the ANNOUNCE trial suggested potential explanations for why there were such different outcomes across 2 of its trials.
The FDA has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Lilly is working to establish an access program to provide Lartruvo to patients who wish to continue treatment.
Detection across tumor types supports the use of next-generation sequencing.
This study used comprehensive microarray analysis of serum to identify a panel of 7 miRNAs specific to sarcoma.
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.
FDA issued a statement recommending against the use of olaratumab in new patients with sarcoma following the release of negative results from the phase 3 ANNOUNCE trial.
Results from a phase 1 study suggest that larotrectinib could be a new standard of care in TRK-fusion cancers.
Eight in 10 patients with DFSP saw a clinical benefit from treatment with imatinib.
Could sorafenib be the new standard of care for desmoid tumors?
mTOR inhibition is thought to enhance the efficacy of chemotherapy.
The outcomes of patients with ESTS did not improve as a result of induction ILP prior to surgical intervention.
The researchers conducted a retrospective cohort study of patients with advanced STS treated at a single institution over a 12 month period.
Next generation sequencing (NGS) may be highly beneficial in select patients with sarcoma.
Approximately 70% of patients were administered anthracyclines as a primary therapy across patient datasets from France, Germany, Spain, and Italy.
Responses to crizotinib in ALK+ inflammatory myofibroblastic tumors were consistent with responses in ALK+ NSCLC, according to presenter Dr Schöffski.
Durable responses to treatment with atezolizumab in advanced alveolar soft part sarcoma were seen across a phase 2 study.
Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.